NCT07054801View on ClinicalTrials.gov

IA Lidocaine and Methylprednisolone for Headache Associated With Subarachnoid Hemorrhage

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

January 1, 2027

Study Completion Date

January 1, 2027

Conditions
Headaches Associated With Subarachnoid Hemorrhage (SAH)
Interventions
DRUG

Lidocaine hydrochloride

A total of 20 mg injected in 10 mg doses will be administered over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 40 mg per MMA. The injection will be performed bilaterally, yielding a total dose of 80 mg per patient.

DRUG

Methylprednisolone sodium succinate

A total of 10 mg were injected over 5 min into the frontal and parietal branches of each MMA, resulting in a cumulative dose of 20 mg per MMA, yielding a total dose of 40 mg per patient.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER